Drug Trial Radar · NCT02710708
YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China
Last checked: Nov 19, 2026Latest source record: Jun 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,921
Actual
Start
May 27, 2016
Primary completion
Jul 3, 2018
Study completion Jul 3, 2018
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Mar 17, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to assess the safety profile of YAZ in Chinese women, including adverse drug reactions (ADRs). The secondary objectives are to investigate the rate of unintended pregnancies, the cycle control for subjects with and without preceding abortion, the bleeding pattern of subjects with and without preceding abortion (including the abortion-related bleeding pattern) and the efficacy in moderate acne vulgaris. Another objective is to investigate the effect on dysmenorrhea.
Conditions
- Contraception
Interventions
EE20/DRSP (YAZ, BAY86-5300)Drug
YAZ (DRSP 3 mg/EE 20 µg), oral route, 6 cycles of 28 days per cycle, each cycle comprising 24 days of active tablets followed by 4 days of placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with adverse drug reactions (ADRs)Time frame: 6 months
Locations
38 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Beijing, China
Site not named
Beijing, China
Site not named
Beijing, China
Site not named
Beijing, China
Site not named
Beijing, China
Site not named
Beijing, China
Site not named
Beijing, China
Site not named
Shanghai, China
Site not named
Shanghai, China
Site not named
Tianjin, China
Site not named
Xiamen, Fujian, China
Site not named
Guangzhou, Guangdong, China
Site not named
Guangzhou, Guangdong, China
Site not named
Shenzhen, Guangdong, China
Site not named
Liuzhou, Guangxi, China
Site not named
Nanning, Guangxi, China
Site not named
Shijiazhuang, Hebei, China
Site not named
Changshacun, Henan, China
Site not named
Wuhan, Hubei, China
Site not named
Yueyang, Hunan, China
Site not named
Changzhou, Jiangsu, China
Site not named
Nanjing, Jiangsu, China
Site not named
Nanjing, Jiangsu, China
Site not named
Wuxi, Jiangsu, China
Site not named
Nanchang, Jiangxi, China
Site not named
Xi'an, Shaanxi, China
Site not named
Weifang, Shandong, China
Site not named
Weifang, Shandong, China
Site not named
Zibo, Shandong, China
Site not named
Taiyuan, Shanxi, China
Site not named
Chengdu, Sichuan, China
Site not named
Ürümqi, Xinjiang, China
Site not named
Kunming, Yunnan, China
Site not named
Kunming, Yunnan, China
Site not named
Hangzhou, Zhejiang, China
Site not named
Hangzhou, Zhejiang, China
Site not named
Hangzhou, Zhejiang, China
Site not named
Wenzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.